Wave Wants To Put The Joy Back Into Weight-Loss Drugs

The company believes its WVE-007 can improve on GLP-1 agonists by preserving muscle mass while also not interfering with the pleasure of eating. Promising mouse data are still to be confirmed in humans, however.

(Shutterstock)

More from Clinical Trials

More from Therapy Areas